{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:22:17Z","timestamp":1792120937659,"version":"4.4.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Janssen Global Services LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.clml.2023.03.005","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T22:01:56Z","timestamp":1679090516000},"page":"426-437.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-3769","authenticated-orcid":false,"given":"Rafael","family":"Fonseca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9693-2192","authenticated-orcid":false,"given":"Alyshia","family":"Laidlaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Rosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manvir","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Duran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Ammann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.03.005_bib0001","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1002\/ijc.33762","article-title":"Epidemiology, genetics and treatment of multiple myeloma and precursor diseases","volume":"149","author":"Hemminki","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2023.03.005_bib0002","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clml.2023.03.005_bib0003","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1200\/EDBK_159009","article-title":"Updated diagnostic criteria and staging system for multiple myeloma","volume":"36","author":"Rajkumar","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clml.2023.03.005_bib0004","doi-asserted-by":"crossref","first-page":"e1406","DOI":"10.1634\/theoncologist.2020-0141","article-title":"Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment","volume":"25","author":"Ludwig","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2023.03.005_bib0005","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12963-016-0091-3","article-title":"Summarizing health-related quality of life (HRQOL): development and testing of a one-factor model","volume":"14","author":"Yin","year":"2016","journal-title":"Popul Health Metr"},{"key":"10.1016\/j.clml.2023.03.005_bib0006","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.clml.2018.08.019","article-title":"Health-related quality of life of patients with multiple myeloma treated in routine clinical practice in France","volume":"19","author":"Despi\u00e9gel","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2023.03.005_bib0007","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/leu.2013.185","article-title":"Review of health-related quality of life data in multiple myeloma patients treated with novel agents","volume":"27","author":"Sonneveld","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.03.005_bib0008","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3109\/10428194.2013.847933","article-title":"Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged \u2265 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial","volume":"55","author":"Dimopoulos","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.03.005_bib0009","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3324\/haematol.2015.127860","article-title":"Health-related quality of life in patients with multiple myeloma\u2013does it matter?","volume":"100","author":"Kvam","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2023.03.005_bib0010","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1182\/bloodadvances.2021004190","article-title":"Assessment and reporting of quality-of-life measures in pivotal clinical trials of hematological malignancies","volume":"5","author":"Al Hadidi","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.03.005_bib0011","first-page":"513","article-title":"Patient-reported outcomes and assessment of quality of life: a focus on multiple myeloma","volume":"11","author":"Fragola","year":"2020","journal-title":"J Adv Pract Oncol"},{"key":"10.1016\/j.clml.2023.03.005_bib0012","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.clml.2022.01.009","article-title":"Patient-reported outcomes in randomized controlled trials of patients with multiple myeloma: a systematic literature review of studies published between 2014 and 2021","volume":"22","author":"Efficace","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2023.03.005_bib0013","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1200\/CCI.20.00100","article-title":"Health-related quality of life data in cancer clinical trials for drug registration: the value beyond reimbursement","volume":"5","author":"Wasalski","year":"2021","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.clml.2023.03.005_bib0014","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.clml.2023.03.005_bib0015","unstructured":"Higgins JPTTJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA Cochrane handbook for systematic reviews of interventions version 6.3 [Internet]. Chichester (UK). 2022. Available at: www.training.cochrane.org\/handbook. Accessed 20 Jan. 2022."},{"key":"10.1016\/j.clml.2023.03.005_bib0016","series-title":"DistillerSR [Computer Program]","year":"2011"},{"key":"10.1016\/j.clml.2023.03.005_bib0017","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/jama.2020.0656","article-title":"Explaining health state utility assessment","volume":"323","author":"Chang","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2023.03.005_bib0018","unstructured":"Papaioannou D, Brazier J, Paisley S NICE DSU technical support document 9: the identification, review and synthesis of health state utility values from the literature [Internet]. 2010: Available at: http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2016\/2003\/TSD2019-HSUV-values_FINAL.pdf. Accessed 5 May 2022."},{"issue":"6","key":"10.1016\/j.clml.2023.03.005_bib0019","doi-asserted-by":"crossref","first-page":"e392","DOI":"10.3747\/co.19.1004","article-title":"Cost-effectiveness of zoledronic acid compared with clodronate in multiple myeloma","volume":"19","author":"Delea","year":"2012","journal-title":"Curr Oncol"},{"issue":"3","key":"10.1016\/j.clml.2023.03.005_bib0020","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3111\/13696998.2011.653511","article-title":"Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective","volume":"15","author":"Delea","year":"2012","journal-title":"J Med Eco"},{"issue":"1","key":"10.1016\/j.clml.2023.03.005_bib0021","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1017\/S0266462313000615","article-title":"Comparative cost-effectiveness models for the treatment of multiple myeloma","volume":"30","author":"Cooper","year":"2014","journal-title":"Int J Technol Assess Health Care"},{"issue":"12","key":"10.1016\/j.clml.2023.03.005_bib0022","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1007\/s00277-018-3446-y","article-title":"Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect MM Registry","volume":"97","author":"Abonour","year":"2018","journal-title":"Ann Hematol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.03.005_bib0023","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood-2020-136677","article-title":"Health state utility valuation in patients with triple-class-exposed relapsed and refractory multiple myeloma treated with the Bcma-Directed CAR T Cell Therapy, Idecabtagene Vicleucel (ide-cel, bb2121): results from the Karmma Trial","volume":"136","author":"Delforge","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2023.03.005_bib0024","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.clml.2015.05.007","article-title":"Pomalidomide and low-dose dexamethasone improves health-related quality of life and prolongs time to worsening in relapsed\/refractory patients with multiple myeloma enrolled in the MM-003 randomized phase III Trial","volume":"15","author":"Weisel","year":"2015","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.clml.2023.03.005_bib0025","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s12885-016-2410-2","article-title":"The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study","volume":"16","author":"Ramsenthaler","year":"2016","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.clml.2023.03.005_bib0026","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.2005.04.0824","article-title":"Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma","volume":"24","author":"Dubois","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.03.005_bib0027","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/10428194.2020.1817439","article-title":"Impact of response to treatment in health-related quality of life patient-reported outcomes in elderly patients with relapsed multiple myeloma","volume":"62","author":"Oriol","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.clml.2023.03.005_bib0028","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s00277-011-1224-1","article-title":"Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial","volume":"90","author":"Verelst","year":"2011","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.clml.2023.03.005_bib0029","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1016\/j.clml.2020.10.002","article-title":"Real-world evaluation of health-related quality of life in patients with multiple myeloma from Germany","volume":"21","author":"Engelhardt","year":"2021","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"issue":"8","key":"10.1016\/j.clml.2023.03.005_bib0030","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/ajh.25134","article-title":"Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed\/refractory multiple myeloma","volume":"93","author":"Leleu","year":"2018","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.clml.2023.03.005_bib0031","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/bjh.14058","article-title":"The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials","volume":"174","author":"Robinson","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2023.03.005_bib0032","doi-asserted-by":"crossref","DOI":"10.4084\/MJHID.2021.034","article-title":"Cost-effectiveness of post-autotransplant lenalidomide in persons with multiple myeloma","volume":"13","author":"Marchetti","year":"2021","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.03.005_bib0033","first-page":"157","article-title":"Health-related quality of life (HRQOL) reported by patients with multiple myeloma (MM) in Germany","volume":"43","author":"Engelhardt","year":"2020","journal-title":"Oncol Res Treat"},{"issue":"2","key":"10.1016\/j.clml.2023.03.005_bib0034","first-page":"599","article-title":"Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey","volume":"21","author":"Acaster","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2023.03.005_bib0035","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-019-0181-0","article-title":"Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed\/refractory multiple myeloma","volume":"9","author":"Ludwig","year":"2019","journal-title":"Blood Cancer J"},{"issue":"32","key":"10.1016\/j.clml.2023.03.005_bib0036","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2016.66.9648","article-title":"Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma","volume":"34","author":"Stewart","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.03.005_bib0037","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/bloodadvances.2021005913","article-title":"Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"6","author":"Delforge","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2023.03.005_bib0038","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/bjh.17321","article-title":"Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial","volume":"193","author":"Hungria","year":"2021","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2023.03.005_bib0039","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1046\/j.1365-2141.1996.352889.x","article-title":"Measurement of health-related quality of life in multiple myeloma","volume":"92","author":"Wisloff","year":"1996","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.03.005_bib0040","first-page":"793","article-title":"Impact of depth of response and minimal residual disease on health-related quality of life of transplant-ineligible patients with newly-diagnosed multiple myeloma","volume":"4","author":"Penaloza-Ramos","year":"2020","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2023.03.005_bib0041","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1186\/s12885-021-08325-2","article-title":"Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial","volume":"21","author":"Knop","year":"2021","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.clml.2023.03.005_bib0042","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.20.01370","article-title":"Health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: findings from the phase III MAIA trial","volume":"39","author":"Perrot","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.03.005_bib0043","first-page":"12","article-title":"Prevalence of chemotherapy-induced peripheral neuropathy in multiple myeloma patients and its impact on quality of life: a single center cross-sectional study","author":"Selvy","year":"2021","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.clml.2023.03.005_bib0044","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3109\/10428194.2013.847933","article-title":"Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged >= 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial","volume":"55","author":"Dimopoulos","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"1\u20134","key":"10.1016\/j.clml.2023.03.005_bib0045","first-page":"337","article-title":"Measuring quality of life in multiple myeloma","volume":"6","author":"Wisloff","year":"1998","journal-title":"Cancer Res Ther Control"},{"key":"10.1016\/j.clml.2023.03.005_bib0046","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/bjh.17435","article-title":"Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial","volume":"194","author":"Plesner","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2023.03.005_bib0047","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1600-0609.2012.01788.x","article-title":"Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial","volume":"89","author":"Delforge","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2023.03.005_bib0048","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/17474086.2020.1746639","article-title":"Cost-effectiveness of once weekly carfilzomib 70 mg\/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States","volume":"13","author":"Kumar","year":"2020","journal-title":"Expert Rev Hematol"},{"issue":"11","key":"10.1016\/j.clml.2023.03.005_bib0049","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1080\/13696998.2016.1194278","article-title":"Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective","volume":"19","author":"Jakubowiak","year":"2016","journal-title":"J Med Econ"},{"issue":"11","key":"10.1016\/j.clml.2023.03.005_bib0050","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s40273-021-01068-9","article-title":"Cost effectiveness of triplet selinexor-bortezomib-dexamethasone (XVd) in previously treated Multiple Myeloma (MM) based on results from the phase III BOSTON trial","volume":"39","author":"Dolph","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.clml.2023.03.005_bib0051","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.clinthera.2019.12.007","article-title":"Economic evaluation of adding daratumumab to a regimen of bortezomib\u00a0+\u00a0dexamethasone in relapsed or refractory multiple myeloma: based on the latest updated analysis of CASTOR","volume":"42","author":"Zeng","year":"2020","journal-title":"Clin Ther"},{"issue":"11","key":"10.1016\/j.clml.2023.03.005_bib0052","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/s41409-019-0574-5","article-title":"Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant of hematopoietic progenitor cells","volume":"54","author":"Olry de Labry Lima","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.clml.2023.03.005_bib0053","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3111\/13696998.2015.1115407","article-title":"Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma","volume":"19","author":"Usmani","year":"2016","journal-title":"J Med Econ"},{"key":"10.1016\/j.clml.2023.03.005_bib0054","first-page":"1691","article-title":"Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma","volume":"27","author":"Narsipur","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"issue":"7","key":"10.1016\/j.clml.2023.03.005_bib0055","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.clinthera.2018.05.012","article-title":"Cost-effectiveness of daratumumab-based triplet therapies in patients with relapsed or refractory multiple myeloma","volume":"40","author":"Zhang","year":"2018","journal-title":"Clin Ther"},{"issue":"5","key":"10.1016\/j.clml.2023.03.005_bib0056","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/ejh.13497","article-title":"Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: a pharmaco-economic assessment","volume":"105","author":"Uyl-de Groot","year":"2020","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1016\/j.clml.2023.03.005_bib0057","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3109\/0284186X.2015.1096021","article-title":"Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden","volume":"55","author":"Borg","year":"2016","journal-title":"Acta Oncol (Madr)"},{"key":"10.1016\/j.clml.2023.03.005_bib0058","article-title":"Cost-effectiveness analysis of adding daratumumab to bortezomib, melphalan, and prednisone for untreated multiple myeloma","volume":"12","author":"Cao","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clml.2023.03.005_bib0059","doi-asserted-by":"crossref","first-page":"e7220","DOI":"10.5867\/medwave.2018.03.7220","article-title":"Cost-effectiveness of lenalidomide in combination with dexamethasone compared to bortezomib in combination with dexamethasone for the second-line treatment of multiple myeloma in Chile","volume":"18","author":"Aceituno","year":"2018","journal-title":"Medwave"},{"issue":"12","key":"10.1016\/j.clml.2023.03.005_bib0060","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2217\/cer-2019-0052","article-title":"Cost-effectiveness of lenalidomide plus low-dose dexamethasone for newly diagnosed multiple myeloma patients ineligible for stem cell transplantation in China","volume":"8","author":"Lu","year":"2019","journal-title":"J Comp Eff Res"},{"issue":"10","key":"10.1016\/j.clml.2023.03.005_bib0061","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/j.clinthera.2017.08.010","article-title":"Cost-effectiveness of pomalidomide, carfilzomib, and daratumumab for the treatment of patients with heavily pretreated relapsed-refractory multiple myeloma in the United States","volume":"39","author":"Pelligra","year":"2017","journal-title":"Clin Ther"},{"issue":"12","key":"10.1016\/j.clml.2023.03.005_bib0062","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1080\/17474086.2017.1391088","article-title":"Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States","volume":"10","author":"Jakubowiak","year":"2017","journal-title":"Expert Rev Hematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023000915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023000915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:33Z","timestamp":1761871293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023000915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S2152265023000915"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.03.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}